CD274 and non-small cell lung carcinoma: Programmed death-ligand 1 (PD-L1) is a useful predictive marker of response for different checkpoint inhibitors and diseases.7 Specifically, the expression of PD-L1 in NSCLC was identified as a useful biomarker to predict benefits from checkpoint inhibitors, namely, pembrolizumab, and the US Food and Drug Administration (FDA) approval of this medication for lung can-cer was based on the expression of PD-L1.